EGFR and lung adenocarcinoma: Our study aimed to investigate the potential of a time-variable radiomics signatures derived from time-serial CT scans to accurately predict progression-free survival (PFS) and stratify the risk of acquired resistance in lung adenocarcinoma patients undergoing EGFR-TKI treatment.